Ausgabe 10/2017
Inhalt (21 Artikel)
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy
Frederik A. Verburg, Markus Luster
Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis
Thomas J. W. Klein Nulent, Robert J. J. van Es, Gerard C. Krijger, Remco de Bree, Stefan M. Willems, Bart de Keizer
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions
Stefano Fanti, Silvia Minozzi, Joshua James Morigi, Frederik Giesel, Francesco Ceci, Christian Uprimny, Michael S. Hofman, Matthias Eiber, Sarah Schwarzenbock, Paolo Castellucci, Cristina Bellisario, Stéphane Chauvie, Fabrizio Bergesio, Louise Emmett, Uwe Haberkorn, Irene Virgolini, Markus Schwaiger, Rodney J. Hicks, Bernd J. Krause, Arturo Chiti
Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI
Ali Afshar-Oromieh, Maya Wolf, Uwe Haberkorn, Marc Kachelrieß, Regula Gnirs, Klaus Kopka, Heinz-Peter Schlemmer, Martin T. Freitag
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, Clemens Decristoforo, Dorota Kendler, Elisabeth von Guggenberg, Bernhard Nilica, Johanna Maffey-Steffan, Gianpaolo di Santo, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging
Kilian Schiller, K. Sauter, S. Dewes, M. Eiber, T. Maurer, J. Gschwend, S. E. Combs, G. Habl
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, Andres Jan Schrader, Michael Schäfers, Martin Bögemann, Kambiz Rahbar
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Yong Du, Ignasi Carrio, Giuseppe De Vincentis, Stefano Fanti, Harun Ilhan, Caroline Mommsen, Egbert Nitzsche, Francis Sundram, Wouter Vogel, Wim Oyen, Val Lewington
Players of ‘hypoxia orchestra’ – what is the role of FMISO?
Takuya Toyonaga, Kenji Hirata, Tohru Shiga, Tamaki Nagara
Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer
Milan Grkovski, Nancy Y. Lee, Heiko Schöder, Sean D. Carlin, Bradley J. Beattie, Nadeem Riaz, Jonathan E. Leeman, Joseph A. O’Donoghue, John L. Humm
SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?
Anna Margherita Maffione, Francesco Giammarile, Domenico Rubello
68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging
Lilian Yuri Itaya Yamaga, Marcelo L. Cunha, Guilherme C. Campos Neto, Marcio R. T. Garcia, Ji H. Yang, Cleber P. Camacho, Jairo Wagner, Marcelo B. G. Funari
Clinical impact of PET/CT imaging after adjuvant therapy in patients with oral cavity squamous cell carcinoma
Huan-Chun Lin, Chung-Jan Kang, Shiang-Fu Huang, Hung-Ming Wang, Chien-Yu Lin, Li-Yu Lee, Chun-Ta Liao, Tzu-Chen Yen
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
[18]Fluorodeoxyglucose Positron Emission Tomography for the Textural Features of Cervical Cancer Associated with Lymph Node Metastasis and Histological Type
Wei-Chih Shen, Shang-Wen Chen, Ji-An Liang, Te-Chun Hsieh, Kuo-Yang Yen, Chia-Hung Kao
The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab
Shuren Li, Markus Peck-Radosavljevic, Philipp Ubl, Wolfgang Wadsak, Markus Mitterhauser, Eva Rainer, Matthias Pinter, Hao Wang, Christian Nanoff, Klaus Kaczirek, Alexander Haug, Marcus Hacker
Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI
Julian Kirchner, Cornelius Deuschl, Bernd Schweiger, Ken Herrmann, Michael Forsting, Christian Buchbender, Gerald Antoch, Lale Umutlu
PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies
Giampiero Giovacchini, Elisabetta Giovannini, Rossella Leoncini, Mattia Riondato, Andrea Ciarmiello
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Giovanni Paganelli, Maddalena Sansovini, Emanuela Scarpi
F-18 FDG and F-18 Tau PET in posterior cortical atrophy
Madhavi Tripathi, Abhinav Bansal, Vivek Baghel, Praveen Kumar, Chandrasekhar Bal
Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn